Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604247 · ClinicalTrials.gov registry record · NA
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT06604247 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 18 participants.
The verdict
NCT06604247, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objective of this project is to test the association between Cognitive Behavioral Therapy for Insomnia dose (number of sessions), severity of cancer related fatigue, and levels of innate immunity biomarkers. Ultimately, this research will help to develop a better understanding of the underlying mechanisms of cancer related fatigue.
Interventions
- BEHAVIORAL Cognitive Behavioral therapy for insomnia (CBT-I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06604247
The ClinicalTrials.gov registry entry for NCT06604247 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cognitive Behavioral therapy for insomnia (CBT-I) is the first listed.
NCT06604247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06604247 about?
NCT06604247 is a clinical study titled "The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients". The objective of this project is to test the association between Cognitive Behavioral Therapy for Insomnia dose (number of sessions), severity of cancer related fatigue, and levels of innate immunity biomarkers. Ultimately, this research will help to develop a better understanding of the underlying ...
What is the current status of trial NCT06604247?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2020-09-30. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT06604247?
The interventions under investigation include: Cognitive Behavioral therapy for insomnia (CBT-I) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06604247?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.